Efficacy of drug treatments for iMCD
| . | Total cases (N) . | Siltuximab . | P* . | Rituximab or RBT . | P† . | Chemotherapy or corticosteroids . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n) . | First line . | CR . | PR . | NR . | Cases (n) . | First-line . | CR . | PR . | NR . | Cases . | First line . | CR . | PR . | NR . | ||||
| All patients | 43 | 21 | 10 (47.62) | 9 (42.86) | 7 (33.33) | 5 (23.81) | .034 | 25 | 16 (64.0) | 5 (20.0) | 12 (48.0) | 8 (32.0) | .68 | 19 | 13 (68.42) | 2 (15.79) | 10 (52.63) | 7 (36.84) |
| Non-TAFRO | 34 | 14 | 5 (35.71) | 5 (35.71) | 5 (35.71) | 4 (28.57) | .221 | 21 | 15 (71.43) | 3 (14.28) | 10 (47.62) | 8 (38.10) | 1.0 | 14 | 8 (57.14) | 2 (14.29) | 7 (50.0) | 5 (35.71) |
| TAFRO | 9 | 7 | 4 (57.14) | 4 (57.14) | 2 (28.57) | 1 (14.29) | .246 | 4 | 1 (25.0) | 2 (50.0) | 2 (50.0) | 0 (0) | .502 | 5 | 4 (80.0) | 0 (0) | 3 (60.0) | 2 (40.0) |
| . | Total cases (N) . | Siltuximab . | P* . | Rituximab or RBT . | P† . | Chemotherapy or corticosteroids . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n) . | First line . | CR . | PR . | NR . | Cases (n) . | First-line . | CR . | PR . | NR . | Cases . | First line . | CR . | PR . | NR . | ||||
| All patients | 43 | 21 | 10 (47.62) | 9 (42.86) | 7 (33.33) | 5 (23.81) | .034 | 25 | 16 (64.0) | 5 (20.0) | 12 (48.0) | 8 (32.0) | .68 | 19 | 13 (68.42) | 2 (15.79) | 10 (52.63) | 7 (36.84) |
| Non-TAFRO | 34 | 14 | 5 (35.71) | 5 (35.71) | 5 (35.71) | 4 (28.57) | .221 | 21 | 15 (71.43) | 3 (14.28) | 10 (47.62) | 8 (38.10) | 1.0 | 14 | 8 (57.14) | 2 (14.29) | 7 (50.0) | 5 (35.71) |
| TAFRO | 9 | 7 | 4 (57.14) | 4 (57.14) | 2 (28.57) | 1 (14.29) | .246 | 4 | 1 (25.0) | 2 (50.0) | 2 (50.0) | 0 (0) | .502 | 5 | 4 (80.0) | 0 (0) | 3 (60.0) | 2 (40.0) |
Data represent n (%) of patients unless otherwise indicated. Evaluation for initial response and duration from treatment to response are similar to all patients and among the treatment groups. The method of response evaluation for no response means that <50% of CD symptoms and laboratory abnormalities returned to normal or symptoms and/or laboratory abnormalities worsened; partial remission 50% to 99%, CD symptoms and laboratory abnormalities returned to normal; CR 100%, improvement in CD symptoms and laboratory abnormalities. Chemotherapy included cyclophosphamide, hydroxyldoxorubicin, hydrochloride, vincristine, and prednisone.
NR, no response; PR, partial remission; RBT, rituximab-based therapy.
Siltuximab vs chemotherapy or corticosteroids.
Rituximab or rituximab-based therapies vs chemotherapy or corticosteroids.